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ABSTRACT 
 
Acquired Immunodeficiency Syndrome (AIDS) is a result of replication of 
Human Immunodeficiency Virus (HIV-1) in an infected host. Reverse transcriptase 
(RT) enzyme of HIV-1 is a multifunctional enzyme in the life cycle of the virus. Even 
though many compounds have been developed against different aspects of HIV-1, RT 
enzyme is a prime target for the development of drugs against HIV-1 because 
eucaryotic cells do not have RT activity. In order to develop new therapeutic agents 
against HIV-1, nineteen newly synthesized compounds were analyzed for their effects 
on inhibition of RT activity as well as their effects on viability, proliferation, and 
activity of peripheral blood mononuclear cells (PBMC). Finally, mutagenic effects of 
the compounds were investigated. 
Results indicated that AVM 002 and AVM 014 were the most promising 
compounds with 51% and 43% inhibitory effects, respectively on RT enzyme at 100µM 
concentration. The compounds AVM 001, AVM 010, AVM 011, AVM 015 and AVM 
019 also showed inhibitory effects between 24% and 40% at 100µM concentration. 
AVM 002 did not cause any toxic effect on cell viability, proliferation and activation 
until 500µM concentration. Similar to AVM 002, AVM 014 did not show any toxic 
effect on the cell viability until 500µM and 1000µM at the and of 24 hour incubation; 
however, AVM 014 at 500µM and 1000µM resulted in 2-fold decrease in the cell 
viability after 48 and 72 hour incubation, compared to the control. Unlike AVM 002, 
AVM 014 gave rise to 3,4-fold decrease in cell activity at the end of second and third 
day incubation. Moreover, among all of the tested compounds, AVM 010 was the most 
toxic at 500µM and 1000µM compared to the control. Furthermore, all the compounds 
did not show any mutagenic effect on Salmonella typhimurium TA 100 and TA 102 
strains. 
In summary, the results indicate that AVM 002 and AVM 014 is the best 
candidate to be improved in order to reach higher RT enzyme inhibitory effect and 
decreased cytotoxicity profile by slight modifications in compound structure.  
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ÖZ 
 
Acquired Immunodeficiency Syndrome (AIDS), Human Immunodeficiency 
Virus (HIV-1) in enfekte konakçõda çoğalmasõnõn sonucudur. HIV-1in Revers 
transkriptaz (RT) enzimi virüsün hayat döngüsünde çok fonksiyonlu bir enzimdir. HIV-
1in farklõ durumlarõ için pek çok bileşik geliştirilmiş olmasõna rağmen, ökaryotik 
hücrelerin RT aktivitesine sahip olmamalarõ, RT enzimini HIV-1e karşõ ilaç 
geliştirilmesinde en önemli hedef yapar. HIV-1e karşõ yeni terapatik bileşiklerin 
geliştirilmesi amacõyla yeni sentezlenmiş ondokuz bileşiğin RT inhibisyon etkileri ve 
aynõ zamanda periferal kan mononüklear  hücrelerinin (PBMC) canlõlõğõna, 
bölünmesine ve aktivasyonuna olan etkileri analiz edildi. Son olarak bileşiklerin 
mutajenik etkileri araştõrõldõ.  
Sonuçlar AVM 002 ve AVM 014ün 100µM konsantrasyonda sõrasõ ile %51 ve 
%43 RT inhibisyonu ile en ümit verici bileşikler olduğunu göstermiştir. AVM 001, 
AVM 010, AVM 011, AVM 015 ve AVM 019, 100µM konsantrasyonda %24-%40 
arasõnda inhibisyon etkisi göstermişlerdir. AVM 002, 100µM ve 500µM 
konsantrasyonlara kadar hücre canlõlõğõ, aktivasyonu ve bölünmesi üzerine herhangi bir 
toksik etkiye neden olmamõştõr. AVM 002ye benzer şekilde, AVM 014 500µM ve 
1000µM konsantrasyonlara kadar, 24 saatin sonunda hücre canlõlõğõ üzerinde toksik etki 
göstermemiş, fakat AVM 014ün 500µM ve 1000µM konsantrasyonlarõ 48 ve 72 
saatlerin sonlarõnda kontrol ile karşõlaştõrõldõğõnda 2 kat düşüşe neden olmuştur. AVM 
014, AVM 002den farklõ olarak ikinci ve üçüncü günlerin sonunda 500µM ve 1000µM 
konsantrasyonlarõ hücre aktivasyonunda 3,4 kat azalmaya neden olmuştur. Dahasõ, tüm 
test edilen bileşikler içinde AVM 010, 1000µM konsantrasyonu kontrol ile 
karşõlaştõrõldõğõnda en toksik bulunmuştur. Ayrõca test edilen bileşikler Salmonella 
typhimurium TA 100 ve TA 102 türleri üzerinde herhangi bir mutajenik etki 
göstermemiştir.  
Özet olarak, AVM 002 ve AVM 014, daha yüksek RT enzim inhibisyon etkisi 
ve düşürülmüş sitotoksik etki elde etmek üzere, bileşik yapõsõnda küçük değişiklikler 
yapõlarak geliştirilmek için en iyi özellikleri göstermiştir.  
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Chapter 1 
 
INTRODUCTION 
 
Since the beginning of the history of humanity, epidemic diseases have been the 
most merciless killer. Plaque had been a horrible nightmare of the middle age people. 
Spanish flu killed nearly 22 million people around the world in 120 days of 1918 and 
today’s modern world AIDS (Acquired Immunodeficiency Syndrome) has been the 
growing epidemic since June 5, 1981 in which Center for Disease Control and 
Prevention published morbidity and mortality generally seen in homosexual men. From 
then on AIDS spreads rapidly especially in sub-Saharan Africa and AIDS has become 
the most devastating disease human kind has ever faced. It is estimated that 40 million 
people were living with HIV at the end of 2001 and more than 60 million people have 
been infected with the virus (http://www.unaids.org). 
AIDS (Acquired Immunodeficiency Syndrome) is the result of the replication of 
Human Immunodeficiecy Virus (HIV). Not all HIV infected person is called as an 
AIDS patient. HIV disease become AIDS when immune system of a body is so 
damaged, immunological abnormalities start to occur. That means having less than 200 
CD4+ cell or opportunistic infections. It is the last period of HIV infections. These 
infections cause weight loss, brain tumors, and other health problems and also can kill 
infected person without treatment. Since the blood cells are very important for infected 
person, an ideal anti-HIV-1 chemotherapeutics should have desired properties. It is 
expected that the therapeutics should reach to desired beneficial effect with minimal 
adverse effects. While no chemicals can be certified as completely “safe” (free of risk) 
since every chemical is toxic at some level of dosage, it is possible to estimate the risk 
associated with exposure to the chemical under specified conditions if appropriate tests 
are performed.  
Substantial amount of medicine against HIV-1 have being developed for the 
treatment of AIDS patience. Because eucaryotic cells do not have reverse transcriptase 
(RT) activity, RT has become one of the most important targets for the development of 
chemotherapic agents against HIV-1. RT shows both RNA and DNA dependent 
polymerase activity, and it converts viral RNA genome into double stranded proviral 
DNA that can integrate into host chromosome. A variety of RT inhibitors classified in 
nucleosid analogues (NRTIs) and non-nucleosid (NNRTIs) have been developed, 
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already. Today, there are two classes of RT inhibitors. These are nucleoside RT 
inihibitors (NRTIs) and non-nucleoside RT inhibitors (NNRTIs). All nucleoside 
analogues (NNRTI) can inhibit RT anzyme in a similar fashion, they work as a chain 
terminator but NNRTIs bind the hydrophobic pocket of HIV-1 RT. Because of the 
binding mode of NNRTIs, they are active only for HIV-1 RT enzyme not HIV-2 (De 
Clercq, 1998). However, each patient shows a different reaction to a specific RT 
inhibitor. In fact, some of the patients cannot tolerate many of the inhibitors. In 
addition, HIV-1 mutates and develops resistance against current drugs. Based on the 
information, it is necessary to continue RT inhibitor development in order to obtain new 
drugs with low toxic effect but maximum RT activity inhibition.  
The aim of this study was to investigate the effects of nineteen benzaxsazole and 
bensimidasole derivatives compounds synthesized by Pharmacology Department of 
Ankara University on Reverse transcriptase enzyme inhibition. These compounds had 
been initially examined by the same research group in order to find their anti-bacterial 
effects but inhibitory effects of the compounds on RT were unknown. Therefore, 
quantitative determination of the enzyme inhibition by these compounds was achieved 
by non-radioactive reverse transcriptase assay in which incorporation of digoxigenin 
and biotin labeled dUTP into DNA by RT was measured as the indicator of enzyme 
activity. In addition, the compounds with RT inhibitory effect were further analyzed for 
their effects on viability, proliferation and activity of peripheral blood mononuclear 
cells in order to determine if these compounds are toxic on the cells. Finally, mutagenic 
effects of the compounds were examined on Salmonella typhimurium strains TA 100 
and TA 102.  
  
 Chapter 2 
 
HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 (HIV) 
                                                                
2.1. HIV-1 
HIV is a lentivirus of the retrovirus Familiy and there are two types of HIV. The 
genomes of two types of HIV-viruses, HIV-1 and HIV-2, differ from each other by 
approximately 50-65 % on the nucleotide level. Originally HIV-1 strains were classified 
into different genetic subtypes by sequencing short genomic fragments, usually from the 
env and gag genes. Especially the env C2V3 gene region has been used frequently for 
subtyping analyses. When the envelope gene region is used, nine subtypes can be 
distinguished (A-H, J), but if the analysis is based on the gag gene, the E subtype strains 
cluster together with the A subtype strains. This has been interpreted such that these 
strains do not represent a single subtype but are A/E recombinants. True E subtype 
strains have not been found so far (Carr et al., 1996, Gao et al., 1996). 
High-resolution electron microscopy of viral particle shows that virions have a 
spherical shape in about 110 nm diameter. Although the overall shape of virions is 
spherical, computer simulations of shadoved replicas and photomicrograps produced by 
scanning electron microscopy suggest that virions are icosodeltahedrons. Nucleocapsid 
is in 100 nm diameter and wide free end is in 40-60 nm, narrow end is in 20 nm width 
(Hirsc et al., 1996).  
Infectious virus contains two single stranded RNA molecules about 9.2 kb long 
as a genomic material. After the entry of virion into the target cell, RNA is converted 
into DNA in the cytoplasm by reverse transcription. Precursor polypeptides for virion 
proteins and several additional open-read frames are encoded in RNA. There are three 
important genes; gag, pol and env. Encoded proteins by these three genes are cleavaged 
by host ezymes and viral enzymes. The gag gene encodes the precursor for virion 
capsid proteins MA, CA and NC, the pol gene encodes polymerase enzymes, and env 
encodes the precursor for envelope glycoproteins gp120 and gp41. The transcriptional 
transactivator (tat) and regulator of viral expression (rev) genes are each encoded by 
two overlapping exons and produce small nonvirion proteins which are essential for 
viral replication. There are also non-essential genes, designated ″accessory’’ or 
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auxiliary genes, encoded by HIV-1. These are vif, vpr, vpu and nef. Products of these 
genes appear not to be packaged into virions (Hirsch et al., 1996). 
As a group, the proviral genomes of primate lentiviruses display a high content 
of adenosine deoxyribonucleotide (A) residues (38% to 39%) and low frequency of 
cytidine deoxyribonucleotide (C) residues (16% to 16%). The generation of a A-rich 
genome may be due to an enzymatic property of RT and/or selective pressure during 
evalution of the virus group. For example the strong bias in the env gene for the triplet 
AAT and related codons favors serine, threonine, and asparagine. This bias appears to 
lead to the creation of new N-linked glycosylation sites, which could enable the virus to 
escape from the host immune response (Hirsch et al., 1996). 
 
2.2. The Viral Enzymes 
 Viral enzymes are encoded by pol gene. Cleavage of the gag-pol polyprotein by 
protease enzyme yields PR, RT (and Rnase H) and IN (Hirsch et al., 1996). 
 
2.2.1. Protease (PR) 
Protease enzyme act as a zymogen and mature PR dimer is released by an 
autocatalytic cleavage possibly by a trans (intermolecular) mechanism. Active protease 
enzyme may be dimer because if protease enzyme is inactivated by site-specific 
mutations in pol gene, uncleaved gag and gag-pol polyproteins are released (Kohl et al., 
1988, Loeb et al., 1989, Manchester et al., 1994). 
In the dimer structure, N- and C-termini of both PR monomers are twisted 
together to form a four-stranded antiparallel β-sheet. The catalytic active site has 
specifity for more than one cleavage site. Upstream of the cleavage site is always 
hydrophobic and unbranched at the β-carbon. PR enzyme is inhibited by blocking 
enzyme dimerization with symetric inhibitors, stericomplementarity compouns of the 
active site (Kuo et al., 1994, Lam et al., 1994, Wlodawer et al., 1993). 
 
2.2.2. Integrase (IN) 
Linear double-stranded viral DNA converted from single stranded RNA by 
reverse transcriptase is inserted into the host cell genome covalently by viral IN 
enzyme. IN enzyme encoded by pol gene is proteolytically processed from Gag-Pol 
precursor polypeptide to yield 32 kd active enzyme (Goff, 1992).  
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The N terminus of HIV IN shows high sequence conservation that contains pairs 
of histidine and cysteine residues (His12, His16, Cys40, Cys43) that can be seen in 
some of DNA-binding proteins. Amino acid residues Asp64, Asp116, and Glu152 
placed in a large central domain of IN are highly conserved in Ins of retroviruses and 
this central domain contains five-strand β-sheet and six helices like Rnase H domain of 
reverse transcriptase enzyme. Active integrase contains two monomers and dimerization 
process is thought to be essential not only for integration but also for assembly of these 
viral enzymes into virus particles. Although a molecule of IN contains a single catalytic 
site, these active sites seem to have separate binding sites for the ends of linear viral 
DNA and double-stranded host cell DNA. IN enzyme recognizes and binds the att sites 
of linear viral DNA and then cuts off a deoxythymidylate (TT) dinucleotide from the 3′ 
ends of double-stranded viral DNA and also host DNA to produce a staggered 5–6 
overhang. 3′ end in the substrate DNA is joined to the 5′ phosphoryl end in target DNA 
(Bushman et al., 1993).  
 
2.2.3. Reverse Transcriptase (RT) 
Reverse transcriptase, a key enzme in viral life cycle, is an RNA-dependent 
DNA polymerse. It converts the single stranded viral RNA molecule into a double 
stranded proviral DNA molecule. Before the discovery of HIV infection, RT enzyme 
was discovered in 1970 by David Baltimore and Howard Temin. Since RT is essential 
for viral replication, it becomes an important target for drugs against AIDS. Enzyme 
consists of two subunits; p51 and p66. Gag-pol polyprotein  (Pr160gag-pol) is cleaved by 
PR enzyme to yield p66, which form a homodimer. Subsequently one subunit of p66 in 
the homodimer is cleaved by PR enzyme near the C-terminus. Occuring heterodimer 
contains two identical units but one of them does not contain RNase H subdomain due 
to the cleavage (Figure 2.1) (Skalka et al., 1993, Hirsch et al., 1996).  
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Figure 2.1. RT enzme p66 is in green colour, p51 is in gold in colour  
(http://chemistry.gsu.edu/CAISER/modules/rt/reverse_transcriptaseh.html) 
 
The active form of HIV-1 RT enzyme is produced in a two-step dimerization 
process. First step of dimerization process is the rapid association of the two subunits, 
and second is following conformational change that gives fully active form (Divita et 
al., 1995, Divita et al., 1995a). The amino acid residues that participate in subunit 
interactios are found in the connection and thumb subdomain of the p51 subunit and in 
the connection and palm subdomains of the p66 subunit, and to a lesser extend, in the 
tip of the thumb subdomain of the p51 subunit and the RNase H region of the p66 
subunit. First step includes interaction of the tryptophan cluster at the interface of the 
connection subdomain of two subunits. Two important triptophan residues 389 to 422 
form hydrophobic patch in the region containing α-helix L and β-strand 19 (Wang et 
al., 1994, Becerra et al., 1991, Baillon et al., 1991). It was found that the N-terminal 
sequence of the Trp cluster is the most efficient in association and dimerization process.  
Conformational change stacks the thumb subdomain of p66 and places the fingers 
subdomain of p51 in the palm subdomain of p66 (Divita et al., 1995). Association and 
activation rate of two subunits have been found to be 5,1x104 M-1 s-1 (May et al., 1999) 
and heterodimer can be formed 10-103 times faster than the p66 homodimer for motion 
(Becerra et al., 1991). Because of the importance of the Trp clusture in formation of 
active RT, synthetic peptides targeting the dimerization process can be used as an anti-
HIV-1 therapeutics. Heterodimers of RT interact in a head-to-tail configuration. 
The p66 subunit contains five subdomains; fingers region, palm region, thumb 
region, connector region, RNase H region. 
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Four subdomains in the p66 subunit of the heterodimer are arranged side-by side 
to yield an elongated RT domain and a connection subdomain in p66 join the RT and 
RNase domain. In this model, the structure of RT looks like a right-hand. The catalytic 
site of RT lies in a cleft in the palm of the p66 subunit and contains the sequence Tyr83-
Met184-Asp185-Asp186. These amino acids are highly conserved not only in retroviral 
RT, but also in other DNA polymerases. In addition, Asp110 also participates in 
catalytic activity (Figure 2.2) (Fields, et al., 1995).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. RT subdomains and catalytic active sites shown in white colour, 
Fingers region (red) Residues 1-90 and 111-160, Palm region (yellow)  Residues 91-
110 and 161-240, Thumb region (orange) Residues 241-310, Connector region 
(cyan) residues 311-430, Rnase H region (purple) Residues 431-end. 
(http://chemistry.gsu.edu/CAISER/modules/rt/reverse_transcriptaseh.html) 
 
After binding of free nucleotides, fingers and thumb subdomains show large 
conformational changes. The finger domain closes down on the palm domain, trapping 
the template strand and the nucleotide. It is assumed that fingers then turn back to the 
open position, releasing the molecule of pyrophosphate leftover from the nucleotide, 
allowing reverse transcriptase to take up the next nucleotide (Fields et al., 1995). These 
are the first two conformational changes. Third change is assumed to position the 
enzyme at the new 3′ end of the growing DNA chain. 
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In this mechanism, while the finger domain (residues 74-78, 89 and 151-152) 
holds the template strand in place, the palm subdomain (residues 110-117, 160-161, 
183-186, and 219-221) positions the nucleotide being incorporated. 
Close positioning of 3′-hydroxyl terminus of primer to the catalytically essential 
Asp110-Asp185-Asp186 residues results in a nucleophilic attack on the α-phosphate of 
an incoming nucleoside triphosphate. Three aspartic acid side chains, oxygen on the α-
phosphate of the nucleotide and possibly with a water molecule produces an octahedral 
shell. Positioning of α-phosphate of nucleotide in this shell gives change for an in-line 
attack by the 3′ hydroxyl group of the complementary strand. The metal ions assist the 
catalysis by juxtaposing the reactive primer hydroxyl with the entropic energy of 
nucleophilic attack. RT incorporates twenty nucleotides into DNA per second (Fields et 
al., 1995). The Km value of RT for dTTP as substrate and poly(rA)oligo(dT)12-18 as a 
primer, derived from Eadie-Hostee plots is 4,6±0,1 µM and kcat value is 1,03± 0,02  s-1 
(Reardon et al., 1995). Hence reverse transcription process occurs in the cytoplasm of 
the infected cell, some reverse transcription seems to be initiated before or during 
assembly of the virion. 
Connection subdomain of HIV-1 RT interacts with template-primer also links 
the RT and RNase H domain. RNase H domain contains two divalent metal ions and 3′ 
end of the template strand contacts the active site of RNase H domain. Backbone 
phosphates of the template interact with these metal ions (Restle et al., 1990). 
Interactions between the two connector regions and between thumb on the p51 subunit 
and RNase H domain on the p66 stabilize the heterodimer form of HIV-1 RT. While 
viral DNA is synthesized, RNase H subdomain degrades viral RNA at the 3′ position, 
16 to 18 nucleotides away from the site of synthesis. 
Activity of reverse transcriptase is a key factor to explain viral diversity. All RTs 
lack the 3′! 5′ exonuclease activity necessary for proof-reading during DNA synthesis.  
In other words, extremely tolerant of non-standart base pairs and modified ribose units. 
The misincorporation rate is about 1/1700 to 1/4000 bases, but some bases in genome 
misincorporation rate increases to 1/30 bases. It means in each replicative cycle 10 
bases change in HIV-1 genome (Lori et al., 1992). This high mutation rate can explain 
how virus can escape from immune responses. It can also generate resistancy for anti-
HIV chemotherapeutics. In addition to direct misincorporation, slippage of the two 
DNA strands at repetitive sequences can cause a deletion (unpaired nucleotide(s) in 
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template strand) or addition (unpaired nucleotide(s) in the primer strand). Moreover, 
frameshifts are caused by misincorporation followed by misalignment of the template-
primer. The most common type of mutations observed in vivo is point mutations. These 
are simply caused by the incorporation of a wrong nucleotide to the growing chain. A 
tpical feature of a lentiviral RT is a bias to induce G!A mutations, which creates 
hypermutant genomes (Vartanian, et al., 1991). This might contribute to the high A 
content of lentivirus genomes. 
Each of these mechanisms can yield single nucleotide mutations and may also 
operate over large distances to produce changes involving many nucleotides.  
 
2.3. Life Cycle of HIV-1 
Viral life cycle can be divided into two phases; early and late phases. Binding of 
gp 120 to the CD4 receptor starts viral infection. After attachment, gp 41 mediates the 
insertion of nucleocapsid into the cytoplasm where uncoating and reverse transcription 
events occur. Synthesized double stranded proviral DNA is then transported to nucleus 
and inserted into host DNA. This ends the early phase of viral life cycle. In the late 
phase, transcription and processing of viral RNA occure. Unsipliced, singly spliced and 
multiply spliced mRNAs are transported to the cytoplasm and processed to yeald viral 
proteins. Full-length viral transcripts interacts with virion precursor polypeptides and 
accumulate under the host cell plasma membrane to produce immature nucleocapsid.  
 
2.3.1. Virion Attachment and Entry 
Interaction between the extracellular domain (gp 120) of the env and CD4 
antigen give rise to change in conformation of Env gp 41 to produce fusion active site 
(Vartanian et al., 1991,David et al., 1998). D1 immunoglobulin like domain of CD4 
contains a high-affinity binding site for gp 120. Cytoplasmic transmembrane C-terminus 
portion of CD4 is noncovalently associated with src-related tyrosine kinase p56lck that is 
thought to mediate signal transduction. However p56lck is thought to start signal 
transductoion, studies with HeLa cells contains deletion mutations in CD4 cytoplasmic 
tail shows that extracellular domain of CD4 is enough for virus fusion, infectivity and 
syncytium formation, and signal transduction is not neccessary for infectivity (Diomond 
et al., 1990).  
Interaction of gp 120 with CD4 receptor on cell enhances exposure of the V3 
loop. Binding mediated conformational change or presumed way that cleavage of V3 
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loop by cellular protease in plasma membrane (Murakami et al., 1991) after attachment 
leads to dissociation of the gp 120 subunit from the gp 41 subunit in virion membranes 
(Kido et al., 1990). In addition cellular protein disulfide isomerase, localized in plasma 
membrane is thought to reduce critical disulfide bonds in the env gp after virions attach 
to the CD4 receptor. Inhibition of this enzyme results in blocking the viral infectivity 
and presumably leaves gp 120 in unchanged conformation. Change in conformation of 
Env gp is thought that gp 41 subunits within gp 120 oligomers form stable coiled coils 
and this event produces a fusion domain that is inserted into the cell plasma mebrane. In 
this process important role belongs to hydrophobic fusion peptide at the N-terminus of 
gp 41 (amino acid residues 517-527) (Morikawa et al., 1991). Leucine zipper (amino 
acid between Leu 553 and Leu 590) also has a role in fusion (Wild et al., 1994). 
Condensation of receptor is thought to bring cell mebrane and virus membrane in close 
position to fuse each other (Moore et al., 1990).  
CD4 receptor is necessary but not enough to mediate HIV infection. There must 
be an additional (receptor chemokine) receptor on target cell membrane. Chemokines 
are cell surface membrane-bound fusion mediating molecules. The chemokine 
coreceptors are the CXC family (CXCR1 to CXCR5) and the CC family (CCR1 to 
CCR9). Conformational change occurred after gp 120 binding on CD4 is not sufficient 
for fusion. Conformational change produced in the gp 41 by the chemokine receptor is 
the complementary event of membrane fusion of HIV-1 and host cell (White, 1992). 
Selective infection of HIV-1 strains is also explained by differences in chemokine 
coreceptors found in a target cell. When chemokine receptors are accounted, HIV-1 can 
be classified into three main groups. They are T-tropic SI strains that selectively interact 
with the CXCR4 chemokine receptor found on lymphocytes, M-tropic NSI strains that 
interact with the CCR5 chemokine coreceptor and, CCR2 and CCR3 found on 
macrophage. Dual tropic HIV-1 strains can use more than one chemokine coreceptor. 
Lately a cofactor CCR8 has been identified that allow infection of either by T-cell 
tropic or by M- tropic strains of HIV. Mutations in chemokine receptors can help to 
understand how resistancy in some cases is seen but mutations in HIV-1 may 
accomplish this phenomenon (Murdoch et al., 2000). 
 
2.3.2. Reverse Transcription 
Reverse transcription of viral single stranded RNA molecule into double 
stranded DNA molecule is started at primer binding site (PBS) from 3′ CCA end of the 
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tRNAlys that bind PBS by hydrogen bonds. In this process RT makes two jump or strand 
transfer. First strand trasfer occurs when RT comes to a strong stop sequence at short 
repeat (R) of 5′ end of viral RNA genome (Montano et al., 1997, De Stefano et al., 
1991). Pausing of the enzyme during synthesis promotes strand transfer (Schatz et al., 
1990, DeStefano et al., 1991). RNase H activity, subsequently, degrades RNA 
molecule. Synthesized R sequence of (-) strand DNA is complementary to 3′ R 
sequence of viral RNA. First jump to the 3′ gives change to match both R sequence and 
to continue (-) strand elongation on the viral RNA template through U3 and into the 
viral genome. RNase activity leaves polypurine tract (PPT) at 3′ sequence of 3′ LTR. 
PPT serves as a start point for (+) strand DNA. Second jump is neccessary to continue 
(+) strand DNA synthesis and it occurs through 3′ PBS. Base pairing between two PBSs 
is formed and (+) strand completion gives full-length double stranded proviral DNA 
that is ready to be integrated into the host cell genome (Delwart et al., 1990, Buiser et 
al., 1993).  
 
2.3.3. Integration of Proviral DNA Trancription of Viral mRNAs 
Translocation of preintegration complex into nucleus is an active transport 
process. It is mediated by nuclear localization signals in MA or Vpr. Integration is not 
random (Peliska et al., 1992, Varmus et al., 1989). HIV-1 genome is generally inserted 
into or near two repeated DNA elements in the human genome: the L1 and Alu 
elements (Shin et al., 1988). These are also called as retroposons that may make 
chromatin structure attractive for integration. IN generally prefers DNA segments 
having a wide major groove or pre-existing deformations of DNA within the 
nucleosome core for integration (Stevens et al., 1994, Preston et al., 1988).  
A protein, integrase interactor 1 (Ini 1) was found to bind to HIV IN and 
stimulate its DNA joining activity in vitro.  
Integration of proviral DNA into host genome leaves single-stranded gaps and 
two mismatched nucleotides at each 5′ terminus. Host cell enzymes remove the 
mismatched nucleotides, fill in the gaps, and nick seal the remaining ends. 
Control of viral transcripts level is mediated by tat and rev viral proteins. U3, R 
and U5 domains in LTR show different functions in viral gene expression. The U3 
domain contains TATAA box as an initiation site of host RNA polymerase II, and sites 
for binding the cellular transcription factor SP1. Initiation of the viral transcripts occurs 
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at the U3/R border of the LTR sequence. In R sequence tat binding site tat-response 
element (TAR) is located. Rev controls the ratio of spliced to unspliced viral mRNA 
and functions through a Rev-response element (RRE) in the full-lenght transcripts. Rev 
gene product also mediates transport of viral RNA from the nucleus to the cytoplasm. 
Synthesized viral mRNAs are transported to the cytoplasm and translated into proteins 
by host cell mechanisms. Full-length messenger RNA (mRNA) transcripts are produced 
from the provirus and are used for translation of Gag and Gag-Pol polyproteins, or they 
can be spliced into smaller mRNAs that are used to produce Env proteins and the non-
structural proteins. Full-length transcripts are also used as genomic RNA that is 
packaged into new progeny virions (Pryciak et al., 1992). 
Cellular cytokines such as tumor necrosis factor a (TNF-a) can activate 
quiescent T cells (and at the same time it also activates HIV-1 replication) by inducing 
nuclear factor kB (NFkB) in the host cell, which in turn binds to specific enhancer 
motifs in DNA and activates transcription (Tscherning et al., 1998). HIV-1 has two 
NFkB binding sites in the U3 region of the LTR, while HIV-2 and SIV only have one 
site. In addition, HIV-1 subtype C has been reported to possess three NFkB sites instead 
of the normal two and it has been speculated that it might influence the higher 
pathogenicity of this subtype (Nabel 1997, Johansson et al., 1995, Gao et al., 1996b, 
Salminen et al., 1996). Also the A/E strains prevalent in Southeast Asia have been 
found to contain one functional NFkB site and one variant site with reduced activity 
(Montano et al., 1997) 
 
2.3.4. Virion Assambly and Maturation 
Interaction of gag polyprotein Pr55gag  (Geldable, 1991, Vaishnav et al., 1991) 
produces an assembly intermediate in the cell cytosol. Nucleoprotein complex contains 
Pro55gag and gag-pol polyprotein Pr160 gag-pol and genomic viral RNA. Packaging 
element (psi) located at the 5′ end of full-length viral RNA is recognized by NC domain 
in the gag polyprotein. After the insertion of Env gp oligomers into host cell membrane, 
MA domain of Pr 55 gag interacts with the cytoplasmic tail of the TM subdomain in the 
Env oligomer. Budding of the viral nucleoprotein complex through the plasma 
membrane gives immature viral particles. Gag, Gag-Pol and Env gp procursors are 
processed to reach infective mature viral particles (Kohl et al., 1988). 
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2.4. RT Inhibitors 
Finding of suramin to protect human T lymphocytes against the infectivity and 
cytopathicity of HIV has started the anti-HIV chemotherapy (Wills et al., 1991). Shortly 
after, successful isolation of HIV in cell culture (Mitsuya et al., 1984, Barre-Sinoussi et 
al., 1983), inhibitory effects of suramin and polyoxometalate HPA 23 (Popovic et al., 
1984) on RT was shown. But suramin was discontinued as a therapeutic modality for 
the treatment of HIV infections because additional short-term clinical studies showed 
that it is too toxic and of little, if any, clinical benefit (Rozenbaum et al., 1985).  
The replicative cycle of HIV gives excellent targets for chemotherapeutical 
aims. These targets are; 
i. Viral adsorption to the cell membrane  
ii. Fusion between the viral envelope and the cell membrane 
iii. Uncoating of the viral nucleocapsid 
iv. Reverse transcription of the viral RNA to proviral DNA 
v. Integration of the proviral DNA to the cellular genome 
vi. DNA replication 
vii. Transcription of the proviral DNA to RNA 
viii. Translation of the viral precursor mRNA to mature mRNA 
ix. Maturation of the viral precursor proteins by proteolysis, myristylation, 
and glycosylation 
x. Budding, virion assembly and release 
Since RT is essential for virus replication and has no closely related identified 
cellular homolog, it has been the prime target for antiviral therapy against the AIDS  
(Kaplan et al., 1987). After discovery of AZT (3′-azido-2′, 3′-dideoxythymidine) to 
inhibit reverse transcription selectively both in vitro and in vivo, the search for clinicaly 
useful drugs for treatment of AIDS was initially focussed on inhibition of HIV reverse 
transcriptase enzyme (De Clerck, 1992). Together with nucleosid analogues there are 
two more classes of inhibitors approved by FDA for chemotherapy of AIDS. Other two 
classes are non-nucleosideinhibitors of RT and protease inhibitors. 
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2.4.1. Nucleoside Analogues 
 
Nucleoside analogue inhibitors (NRTIs) of RT enzyme of HIV-1 were the first 
class of compounds to be used in anti-HIV-1 therapy. The first approved drug AZT 
(zidovudine) belongs to the 2′,3′-dideoxy class of nucleoside analogues. Other members 
of this class of compounds are d4T (stavudine), ddI (didanosine), ddC (zalcitabine), the 
heterosubstituted (-)- enantiomer of 2′-deoxy-3′-thiacytidine, 3TC, and the carbocyclic 
analogue abacavir (1592U84) (Duluge et al., 1997). All approved nucleoside analogue 
inhibitors of RT are 2′,3′-dideoxyl derivatives of  the natural nucleotide substrates of 
DNA polymerases. They show their inhibitory effect in the same way (Figure 2.3). It 
can be said that all nucleoside analogues can be inhibitors of RT but small 
modifications of chemical structure can change their properties such as their inhibitory 
activity and toxic effects on the organism. 
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Figure 2.3. Chain termination by NRTI 
 
First step (Figure2.4) is the formation of the monophosphate (Step A) second 
step, the formation of diphosphate (Step B) by nucleotide kinases is followed by 
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formation of triphosphate (Step C) results from the action of nucleoside kinases or other 
less specific phosphorylation enzymes.  
(http://www.bristol.com.br/mediços/infocientifica/6/default.htm) 
 
 
Figure 2.4. Phosphorylation of natural D-2′-dideoxynucleotides 
 
First thymine analogue AZT is converted into monophosphate form easily but 3′ 
N3 group of this compound causes trouble in work of enzyme in Step B. This 
phenomenon shows that activity of nucleosid analogues depend on the substrate activity 
of kinase enzymes. Zerit (stavudine, d4T) was synthesized to deal with this problem 
by modifiying chemical structure of AZT. Change in 3′ N3 group of AZT to H molecule 
improved mono-, di-, triphosphate ratio from 8:1:1 to 1:1:1 (Schmit & Weber, 1998).  
Another nucleoside analogue Abacavir is phosphorylated by different process. 
Intracellularly monophosphate formation is followed by deamination to (-)-corbavir 
triphosphate with catalysis of adenosine deaminase or adenylicasid deaminase. 
Parameter that defines the activity of kinase enzyme is enantioselectivity of the 
enzyme to optic isomers of sugar molecule. Two main carbohydrates found in nucleic 
acids, ribose and deoxyribose are naturally in D-configuration and studies initialy 
focused on analogues in D-conformation. Moidity of analogues that have L-sugar is 
restricted by enantioselectivity of kinase enzymes especially act in step A (Figure 2.5) 
(Zemlicka, 2000). 
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Figure 2.5. Structure of D- and L-nucleosides 
 
Studies revealed that, stavudine, zidovudine and didanosine show very strict D-
form selectivity. L enantiomer of AZT shows 25,000-fold decline in RT inhibition 
activity. On the other hand, L-enantiomers of nucleoside analogues show limited 
cytotoxicity lower than D forms (Zemlicka, 2000).  
Advers events seen with usage of NRTIs are bone marrow supression, anemia or 
neuropenia, GI intolerance, headache, insomnia, asthenis, pancreatitis, peripheral 
neuropathy, nausea, dierrhea, stomatitis, hypersensitivity reaction and most important 
lactic asisdosis. It is thought that these complications are the results of the toxic effects 
on mitochondria. Competition of analogues with the substrate of mitochondrial 
polymerase-g (mDNA) results in decline in 13 important mitochondrial protein 
(http://www hivinsite .ucsf. edu). 
 
2.4.2. Nonnucleoside RT Inhibitors 
Discovery of 1-(2-hydroxyethoxymethyl)-6-(phenylthio)thymine (HEPT) (Baba 
et al., 1989, Miyasaka et al., 1989) and tetrahydroimidazo[4, 5, 1-jkj][1, 4] 
benzodiazepin-2(1H)-one and –thione (TIBO) (Pauvels et al., 1990, Debyser et al., 
1991) has been showed to inhibit HIV-1 RT specifically, research has been focused on 
NNRTIs. It was followed by the discovery of nevirapine (De Clercq, 1993) 
(diriyridodiazepinones), pyrididone (L-697,661), BHAP (delavirdine, U-90152), and 
other HEPT series compounds (i.e. I-EBU(MKC-442), TIBO series [(8-ckloro-
TIBO(tivirapine, R 86183)] and PETT (trovirdine, LY 300 046). There are now over 30 
compounds that are defined as a specific RT inhibitors (De Cleccq, 1994). 
Trovirdine is the first generation of PETT (phenylethylthiazolythiourea) series. 
Urea analogues obtained from further optimization of PETT series was found to have 
less toxicity than thiyourea compounds (Högberg et al., 1999). 
Nevirapine, delavirdine and efavirenz were approved in all these compounds to 
be used on AIDS patients (De Cleccq, 1994). 
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NNRTIs interact non-competitively with a specific pocket site of HIV-1 RT. 
This pocket is closely associated with, but distinct from the NRTI binding site. The 
distance between two binding site is about 10 Å (Tantillo et al., 1994) and works 
allostericly. The cooperative interaction between these two sites (Spence et al., 1995) 
provides higher binding activity of NNRTIs to enzyme-substrate complex (Althans et 
al., 1994) than the free enzymes. Cooperative interaction between these two sites 
increases effectiveness of NRTI and NNRTI combination therapy, because binding of 
NNRTI to their hydrophobic pocket decrease the binding rate of substrate into growing 
DNA. NNRTIs are only effective for HIV-1 RT because of the presence of highly 
hydrophobic flexible pocket that is not seen in any RTs or DNA polymerases 
(Kohlstaedt et al., 1992, Nanni et al., 1993). Important amino acids that participate in 
the binding of NNRTIs have been determined by drug resistancy mutations. Leu100, 
Lys103, Val106, Val108, Glu138, Val179, Tyr181, Tyr188, Gly190, Met230, and 
Pro236 were determined as important amino acid residues for inhibitor interaction with 
HIV-1 RT. Except Gly138 localized in p51 subunit, all of these amino acids are 
localized in p66 subunit (De Clerck 1999). 
Commonly seen binding mode of NNRTIs to their binding site cause a 
repositioning of the three-stranded β-sheet in the p66 subunit containing the catalytic 
aspartic acid residues 110, 185, and 186. This conformational change turns active site 
into inactive. α-APA R95 846, 8-chloro-TIBO (R86183) (Ding et al., 1995), 9-chloro-
TIBO [R82913] (Ren et al., 1995) and nevirapine binding to hydrophobic pocket of RT 
cause to change conformation into butterfly-like shape. It is suggested that these 
inhibitors act as π-electron donors to aromatic side-chain residues surrounding the 
pocket (Kroger, et al., 1995). 
When delavirdine binds into the pocket, H-bonding to the main chain of Lys103 
and extensive hydrophobic contacts with Pro236 stabilize the complex. Binding of U-
90152 creates a channel between Pro236 and the polypeptide segment 225-226 and 150-
106. The thiocarboxyanilides bind the pocket through hydrogen bonding with the main 
chain oxygen of Lys101 and hydrophobic interactions with Leu100, Val106, Val179, 
Tyr188, Phe227, Leu234 and His235, also Trp229 participate hydrophobic binding 
when thiocarboxanilide UC-781 interacts with pocket  (Esnoulf et al., 1997, Plemans et 
al., 1998). 
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Unique specificity of NNRTIs makes them more useful than NRTIs such as they 
can inhibite RT in nanomolar concentrations that are at least 100,000 fold lower than 
their toxic concentrations. In addition they do not need phosphorylation process that 
restricts NNRTIs activity and they do not bind other polymerase enzymes (De Clercq, 
1995). 
Drugs used for anti-HIV-1 chemotherapy target the polymerase activity of RT 
but their toxic effects and emergency of drug resistant strains are the forces to develope 
new drug and strategies. DPC 961 with IC50= 0,36 nM and DPC 083 with IC50= 0,4 nM 
were developed for the patients that shıw multi-resistancy to nevirapine, delavirdine and 
efavirenz. DPC 961 is the second generation of efavirenz and developed by change in 
benzoxazine ring into quinaxaline (Bacheler, XIII International AIDS Conference 
Abstracts).  
 
2.4.3. Recent Studies on Newly Synthesized Benzoxazole, Benzimidazole, 
Benzothiazole Derivatives 
Several substituted benzimidazole derivatives have been reported for their 
antimicrobial, antitumor and antiviral activities after thiabendazole (2-[4-thiazolyl] 
benzimidazole) have been found to be effective in the treatment of helmintic diseases 
with blood clinical efficiency. Before that, 2-(α-hydroxybenz )benzimidazole (HBB) 
and 1,2-bis(2-benzimidazolyl)-1,2-ethanediol derivatives were introduced as an 
inhibitor of poliovirus replication (Ören et al., 1997). 
A series of substituted 2-phenylbenzimidazole-4-carboxamides were synthesized 
and eveluated for their antitumoral activity in vitro and in vivo. They were found less 
toxic but some of them had antileucemic effects. In addition, substituted pyrimido[1,6-
a]benzimidazoles were exhibited as a new potent DNA gyrase inhibitors. Recently 
benzoxazoles that are the isoesters of the benzimidazole derivatives, point out potential 
antimicrobial activity with lower toxicity. An antibiotic calcimycin (A 23187) includes 
benzoxazole ring in molecular stracture and weas found to be very effective for gram 
(+) bacteria. Moreover, series of 2-(4-aminophenyl) benzothiazoles substituted in the 
phenyl ring were defined as potent antitumor agents for breast cancer cell lines. 2-(4-
amino-3-methylphenyl)-benzothiazole derivative was found as the most potent 
compound in these series as its activity extends to ovarian, lung and renal cell lines (Shi 
et al., 1996). 
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In addition to these observations both 3-([benzoxazol-2-yl]ethyl-5-ethyl-6-
methylpyridin-2-(1-H)-one (L-696,299) and 3-(4,7,dichlorobenzoxazol-2-yl 
methylamino-5-ethyl-6-methyl-pyridine-2(1H)one, (L-697,661) are benzoxazole 
derivatives and are highly selective inhibitors of HIV-1 RT (Shi et al., 1996). 
Studies on Topoisomerase I revealed that substituted benzimidazoles were 
inhibiting this enzyme with minimum or no DNA binding affinity, also substituted 
pyrimido[1, b-a] benzimidazoles were found to be a new class of potent DNA gyrase 
inhibitors (Hubschwerler et al., 1992).   
Yalçın et al. 1990, 1992 reported antimicrobial activities of various 2,5-
disubstituted benzoxazoles, benzimidazoles, benzothiazoles and oxazolo (4, 5-6) 
pyridines against some gram positive and negative bacteria and the yeast Candida 
albicans. Sicnificant antimicrobial activity was observed on enterobacter Pseudomonas 
aeruginosa and the yeast C. albicans. For Klebsiella pneumoniae and C. albicans, 
oxazolo (4,5-6)pyridine derivatives were observed to have the best inhibitory potency 
and antimicrobial activity (Ören et al., 1997, Yalcın et al., 1990, Yalcın et al., 1992). 
Substituted benzimidazoles, benzoxazoles and related heterocycles, owing fused 
heterocyclic nuclei, are the structural isoesters of nucleotides. These constractions give 
them the chance to interact easily with biopolymers, and decreasing cytotoxic effects 
and increasing chemotherapeutic moidety (Hubschwerlen et al., 1992, Perrin et al., 
1996, Kim et al., 1996, Shi et al., 1996). 
 
2.4.4. The Drug Discovery, Development and Approval Process 
The drug discovery, development and approval process take 15 years on 
average. Among the 5000 compounds tested through preclinical testing, only 5 of them 
were approved to be used on human testing and only one of these five is approved for 
sale. 
In perclinical tests, compounds are tested in the laboratory to answer if the 
compound shows activity against target disease or not, and evaluate for safety. First step 
of this process is performed by using cells that can be special cell lines or blood cells 
directly taken from patients or healthy volunteers then animal tests are applied. 
Preclinical tests are followed by clinical trails to determine safety and dosage in healthy 
volunteer. After side effect determination in Phase II and Phase III clinical trails, data of 
compounds are analyzed by FDA (Food and Drug Administration). 
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In order to achive the aim of this study, first stage of preclinical tests was done. 
For this purpose, the inhibitory effects of newly synthesized compounds AVM 001, 
AVM 002, AVM 003, AVM 004, AVM 005, AVM 006, AVM 007, AVM 008, AVM 
009, AVM 010, AVM 011, AVM 012, AVM 013, AVM 014, AVM 015, AVM 016, 
AVM 00,17, AVM 018 and AVM 019 (structures were given in Material Method 
section) on RT enzyme of HIV-1 were determined wether compounds show activity to 
target or not. Subsequently, in order to elucidate the effects on biological system, short-
term cytotoxicity assays were performed and completed as given in the Drug Discovery, 
Development and Approval Process Table 2.1. 
 
 
Table 2.1. Drug discovery, development and approval process 
 
 
 
 
 
 
 
 
 
5,000 
compunds 
evaluated 
Success 
Rate 
Assess safety, 
biological 
activity and 
formulations 
Purpose 
Laboratory and 
animal studies 
Test 
population 
 
6,5 Years 
Evaluate 
efectiveness, 
look for side 
effects 
100 to 500 
patient 
volunteers 
2 
5 
Enter trials 
Confirm 
effectiveness, 
monitor adverse 
reactions from 
long term use 
Determine 
safety and 
dosage 
1,000 to 5,000 
patient volunteers 
20 to100 
healthy 
volunteers 
3,5 1,5 
1 approved 
Review 
process/ 
approval 
1,5 
 
15 total  
 
 
 
 
 
 
Additional 
post-marketing 
testing 
required by 
FDA 
Discovery/ 
preclinical testing Phase I Phase II Phase III FDA Phase IV 
Clinical trials 
  21 
Chapter 3 
 
Materials and Methods 
 
3.1. Materials                     
Reverse Transcriptase Assay, colorimetric kit and heparin-sodium (Lequimine) 
were purchased from Roche. Cell Proliferation assay kit was purchased from Amersham 
Life Science. Roswell Park Memorial Institute (RPMI)-1640 medium, Fetal Bovine 
Serum (FBS), gentamycin sulfate, concanavilin A (con A), trypan blue, MTT, DMSO, 
luria agar were obtained from Sigma Chemical Company. Biocoll cell separation 
solution (Ficoll with desity 1,071 mg/ml) was from Biochrom Chemical Company. 
Potassium monohydrogen phosphate, potassium dihydrogen phosphate, sodium chloride 
were purchased from Merck Chemical Co. Tissue culture plates were from Corning 
Star, polyprophylene tubes and disposable pipettes were obtained from Greiner. 
Calcium phosphate (tri basic) was purchased from Aldrich Chemical Co. Salmonella 
typhimurium strains were obtained from Prof. Bruce Ames (Biochemistry Depertment, 
University of California, Berkeley). Newly synthesized compounds were kindly 
provided by Faculty of Pharmacy, Ankara University. 
 
Compaund 
Code 
Chemical name Chemical Structure 
AVM 001 
 
5-Chloro-2-(p-methyl) 
phenylbenzoxazole 
N
O
Cl
CH3
 
AVM 002 
 
5-Methyl-2-
(phenoxymethyl)benzoxazole CH3
N
O
CH2 O
 
AVM 003 
 
N-(2-hydroxy-4-nytro-5-
chlorophenyl)phenylthioacetamide 
Cl
O2N OH
NH C CH2 S
O
 
AVM 004 
 
2-phenyl-5[(p-propoxyphenyl) 
carbonilamino]benzaxzole 
CH3CH2CH2O C NH
O
N
O
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AVM 005  
2-(phenoxymethyl)benzotiazole 
CH2 O
N
S
 
AVM 006 
 
Methyl ester of 2-phenoxymethyl-
benzoxazole-5-carboxylic acid O
CH3OC
CH2 O
N
O
 
AVM 007  
2-(phenoxy)benzymidazole N
NH
OCH2
 
AVM 008 
 
5-chloro-2-(p-chlorophenyl) 
benzoxazole Cl
Cl
N
O
 
AVM 009 
 
5-chloro-2-(phenyltiomethyl) 
benzoxazole 
S
N
O
Cl
CH2
 
AVM 010 
 
2-(p-chlorophenoxymethyl) 
benzaxozole 
OCH2
N
O
Cl
 
AVM 011  
6-nytro-2-cyclohexyl benzoxazole 
O2N
N
O
 
AVM 012 
 
5-chloro-2-(chloromethyl) 
benzoxazole 
CH2Cl
N
O
Cl
 
AVM 013 
 
2-(p-chlorophenoxymethyl) 
benzimidazole 
CH2
N
NH
ClO
 
AVM 014 
 
2-(p-fluorophenyl)-5-
aminobenzoxazole 
F
N
O
H2N
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AVM 015 
 
 
N-[(2-hidroxy-5-methyl)phenyl]-
2,4-dimethyl-bensamide 
         
NHCH3
CH3
CH3
OH
O
 
 
AVM 016 
 
2-phenyl-5-[(p-methoxyphenyl) 
carbonylamino]benzoxazole 
CH3O NHC N
O
O  
AVM 017 
 
2-cyclopentano-oxozalo(4.5-b) 
pyridine N
O
N
 
AVM 018 
 
5-methyl-2-(21,41-dichlorophenyl) 
benzoxazole 
Cl
Cl
N
O
CH3
 
AVM 019 
 
Ethyl 3,4-dihydro-7-methyl-3-oxo-
2H-1.4-benzoxasine-2-acetate 
OC2H5
H
CCH3
N
O
O
O
CH2
 
 
Table 3.1. Chemical structure of newly synthesized compounds 
 
3.2. Methods 
 
3.2.1. Solubility of Compounds 
Solubility of compounds in solvents is an important parameter for not only 
reverse transcription inhibition experiments but also to test cytotoxicity and cell 
proliferation effects on PBMC. Tested solvents were DMSO, ethanol, methanol and 
lysis buffer of reverse transcriptase assay kit. Each compound was investigated 
according to their behavior in these solvents and also their dilutions in lysis buffer. 
Because of the importance of lysis buffer for normal work of reverse transcriptase assay 
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kit, first solubility test was applied by using lysis buffer. Secondly, solubility of 
compounds in ethanol, methanol and DMSO were investigated. 1 mg compound was 
tried to be solubilzed in 1 ml of pure solvent and pellet formation after centrifugation 
was detected for determination of solubility. Solubilized compounds were hence diluted 
in lysis buffer and RPMI 1640. These diluted samples were also tested for precipitation 
formation in the same way.  
The chosen interval for reverse transcription inhibitory effect of compounds was 
in 0.01–100 µM. Four points in this interval were provided and tested for each 
compound. 60 µl reaction mixture contained 100 µM, 10 µM, 1 µM, 0.01µM 
concentrations in separate wells. Maximum 1000 µM minimum 0.01µM concentrations 
of compounds were selected for blood cell experiments. Experimental calculations were 
arranged to fix solvent concentration at 2 % to prevent any interference of inhibitory 
effect of used solvent on reverse transcriptase. For PBMC cultivation, this concentration 
was fixed at 1% solvent/well. For this purpose, pure solvent serial dilutions were 
prepared, then equal amounts of each concentration were pipetted to add lysis buffer or 
RPMI 1640 according to experimental procedure. All compounds were solubilized 
separately before each experiment was done, then stored at –20°C. 
 
3.2.2. Determination of Reverse Transcriptase Inhibition 
Reverse transcriptase inhibition effects of compounds, DMSO and ethanol were 
measured by using non-radioactive ELISA kit from Roche. The detection and 
quantification of synthesized DNA as a paremeter for RT activity follows a sandwich 
ELISA protocol and the absorbance of incorporation of digoxigenin and biotine-labeled 
dUTP into DNA is directly correlated to the level of RT activity in the sample. Assay 
was performed as described in the protocol included with the kit, except for one hour 
reverse transcriptase incubation step. Briefly, the initial step of the assay is binding of 
biotin and dioxygenin labeled DNA on to the surface of pre-streptovidin coated 
microtiter plate. In the next step, an antibody to dioxygenin, conjugated to peroxidase 
(anti-DIG-POD), binds to the dioxigenin-labeled DNA. In the final step the peroxidase 
substrate ABTS is added. The peroxidase enzyme catalyzes the cleavage of the 
substrate, producing a colored reaction product. In the experimental section, 20 µl 
(4ng/well) recombinant reverse transcriptase enzyme diluted in lysis buffer was pipetted 
into a streptovidin coated microtiter plate per well. As a negative control, 20 µl lysis 
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buffer with no RT was used. Other control was included only RT, no inhibitor. 
Subsequently, 20 µl inhibitor diluted in LB, 20 µl reaction mixture including templete 
and nucleotides were added. Total volume was 60 µl. After 2 hours incubation at 37°C, 
plates were washed with 250 µl washing buffer and added 200 µl of anti-dioxigenin-
peroxidase (Anti-DIG-POD, 200 mU/ml). Following 1 hour incubation at 37°C, plates 
were washed 5 times again and 200 µl ABTS substrate solution/well was added, 
incubated on orbital shaker at 75 rpm, room temperature until sufficient color 
development obtained. Optical density (OD) was measured by microtiter plate (ELISA) 
reader at 405 nm (reference wavelength: 490 nm). Results were expressed as % 
inhibition. This test is the first step for new compounds to find if the compound is 
effective on target or not. Activity of the compounds is expressed as IC50 (50% 
inhibitory concentration or concentration required to inhibit HIV-1 RT activity by 50%) 
valu (De Clercq, 1998). Percent inhibition of RT enzyme was calculated as the formula 
shown below. 
 
% RT inhibition = 1 - [(OD of the Sample – Unspecific Binding)/(OD of the Control– 
Unspecific Binding)]  
 
3.2.3. Isolation of Peripheral Blood Mononuclear Cells 
Current law demands that new drugs, cosmetics, food additives, implants etc. 
should be tested by cytotoxicity tests before they are evaluated clinicaly. In vitro tests 
are not completely related with in vivo activity but can give selective mode of action for 
a compound. In addition, in vitro cytotoxicity tests are now used as an alternative 
method to animal experiments.  In a drug discovery pipeline, cell viability (dye 
exclusion, cell counts), cell metabolism (dye reduction), cell replication (cell 
proliferation) can be investigated. Cytotoxicity assays should be set according to target 
response of cells to the chemicals and blood cells serve as a good source for body 
response, in other word, peripheral blood is the primary source of lymphoid cells for the 
exemination of immune response in humans. Isolated PBMCs contain 5 % B 
lymphocytes, 5-15 % monocytes, 60-70 % T lymphocytes and 5-15 % Natural Killer 
Cells (Reichert et al., 1991). Ficol hypec gradient centrifugation was used for isolation 
of PBMCs. While Ficoll sucrose polymer aggregates the eritrocytes in the bottom, low 
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dencty PBMC and platelets form a layer on the top of gradient. Platelets are removed by 
washing with PBS. 
Heparinized blood was collected from healthy, non-smoking men and women of 
age between 24-30 as described in literatures (Hokland M. et al., 1994). Blood samples 
were diluted with equal volume of 0.9 % NaCl. 5 ml diluted blood was spreaded onto 3 
ml ficol in a conical falcon tubes then cetrifuged at 1600 rpm, 25 °C for 25 min. Buffy 
coat was drived into new tubes by sterile pastor pipet and washed with 10 ml sterile 
phosphate buffered saline (PBS) solution containing 2 % FBS at 800 rpm for 10 min. 
After removing the supernatant by pouring, cells were washed 2 times with PBS at 500 
rpm for 8 min to remove platelets and thrombocytes. The cells were collected into one 
tube with 2 ml RPMI containing 15 % FBS, 50 µg/ml gentamycin solution. 50 µl cell 
suspension was diluted with 50 µl trypan blue solution (0.4 %) then counted with 25 
square hemocytometer under light microscope, and seeded into microtiter plates at 2 x 
105 cell/well density. This formula was used to reach total cell number: 
 
Number of cells/ml = Number of cells counted in 25 square x Dilution factor x 104 
 
3.2.4. The Viability of PBMCs 
Totxic effects of the compounds (AVM 001, AVM 002, AVM 010, AVM 011, 
AVM 014, AVM 015, AVM 019) on the viability of PBMCs were determined by trypan 
blue dye exclusion method. The method depends on a breakdown in membrane 
integrity. However a viable cell is impermeable for uptake of a dye, dead cells become 
permeable and can be distinguished from live cells by their blue color under light 
microscope. This methot is simple method for the determination of the anti-HIV-1 drugs 
CC50 value (CC50 is the inhibitory concentration that reduces cellular growth or viability 
of uninfected cells by 50%) (Lin T.S. et al., 1988). Cells were seeded with filter 
sterilized solution of compounds in 1000 µM-0.01 µM concentration range in 96 well 
flat bottom tissue culture treated plates. Six points of this range were 1000µM, 500 µM, 
100 µM, 10 µM, 0.001 µM. Cells were counted at 24 h, 48 h, and 72 h drug exposure 
periods. At the end of time periods cells were collected slowly in eppendorfs and dead 
and live cells were counted under light microscope with hemocytometer just after 
mixing 50 µl cell suspension and 50 µl trypan blue. The following formula was used to 
calculate cell viability: 
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Percent Cell Viability = [Number of live cells / Number of total cells (live+dead)] x 100 
 
3.2.5. The Proliferation of PBMC 
Effect of compounds AVM 001, AVM 002, AVM 010, AVM 011, AVM 014, 
AVM 015, AVM 019 on proliferation of PBMCs was determined by using cell 
proliferation ELISA system, version 2 from Amersham Life Science. This assay 
depends on the incorporation of pyrimidine analogue BrdU into DNA of proliferating 
cells instead of thymidine. Peroxidase labelled anti-BrdU binds to BrdU in newly 
synthesized cellular DNA. Color formation is achieved after addition of substrate and 
absorbance is measured at 450 nm by ELISA plate reader. Isolated PBMCs were 
incubated for 48 h in a CO2 incubator at 37 °C in a humidified atmospher with 
compounds. At the end of incubation period, BrdU was added and reincubated. After 16 
hours, 96 well plate was centrifuged at 1200 rpm for 15 min, labelling medium was 
removed by gently tapping and cells were dried by hair drier for 15 min. 200 µl 
fixative/well added plate was incubated 60 min at room temperature. After 200 µl 
blocking reagent/well was added 30 min incubation period followed by removing 
solution by tapping and pipetting 100 µl peroxidase-labelled anti-BrdU. 2 h incubation 
period at room temperature was applied before removing unbound substances and 3 
times washing with washing buffer. 100 µl room temperature equilibrated TMB 
substrate solution/well was added and plate was incubated in an orbital shaker at RT 
until required color density was achieved. Color reaction was stopped by pipetting 25 µl 
of 1 M sulphuric acid. Optical density of the samples was measured by ELISA plate 
reader at 450 nm in 5 min. 
 
3.2.6. AMES Mutagenicity Test 
 Salmonella mutagenicity test (AMES) developed by Bruce N. AMES was used 
to determine mutagenic potential of compounds (AVM 001, AVM 002, AVM 010, 
AVM 011, AVM 014, AVM 015, AVM 019). AMES test depends on the histidine 
requirements of the Salmonella typhimurium strains becacause of the mutation in 
histidine operon. This is because tester strains require histidine to grow.  If the strain 
undergoes the beck mutation in the His gene because of the carcinocens it does not 
require histidine anymore. Two histidine-requering strains, TA 100 and TA102 that 
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contain the R-factor plasmid were used to determine mutagenic potential of compounds. 
In addition to R-factor plasmid that increases permeability of cell membrane for large 
molecules because of the partial loss of the lipopolysaccharide barrier, TA102 contains 
PAQ1 mutation which carries the hisG428 mutation and a tetracycline resistance gene. 
PAQ1 mutation can be utilized to detect oxidative mutagens in contrast to the other 
Salmonella tester strains that detect organic carcinogens. Since the plasmid is somewhat 
unstable and can be lost from the bacteria, strains were tested in the presence of the 
ampicillin. The PAQ1 strain (TA102) was tested for both ampicillin and tetracycline 
resistance on ampicillin/tetracycline plates. Reverse mutations of tester strains that show 
resistancy to antibiotics were detected for their histidine dependence or independence. 
   Tester strains TA 100 and TA 102 were grown in nutrient broth no: 2 in 50 ml 
flasks at 37 °C with shaking overnight in thermal shaker for 16 hours as a first step. In 
order to prevent back-mutation cultures were protected from sunlight by covering 
aluminium foil during incubation and experiment. Compounds were solubilized in 
DMSO and tested at 0.01µM, 0.1µM, 1µM, 100µM, 1000µM and 3000µM 
concentrations per plate. Next day, 0.1 ml growing culture, 0.5 ml PBS (pH: 7.4) and 
0.1 ml compound were pipetted in sterile test tubes and mixed slowly by vortex than 
pre-incubated for 1 hour at 37°C with shaking as asecond step. After preincubation 
period, 2 ml top agar containing 0.5 mM Histidine-Biotin was added into tubes, 
vortexed slowly for 3 seconds and poured onto glucose agar plates. Poured mixture was 
uniformly distributed on plate surface. Preperation of pour plate were completed in 20 
seconds. Duplicate plates were incubated at 37°C for 48 hours and the revertant 
colonies with background lawn were counted.  
 Plates containing no compound as a negative control, 5 ml sodium azide (17.2 
mg/ml) as a positive control, and only biotin were compared to determine the mutagenic 
potentials of compounds.  
 
3.2.7. The Activation of PBMC (MTT Assay) 
 The in vitro tetrazolium-based colorimetric assay (MTT) was used to detect the 
activation of PBMC. This assay also represents cytotoxic effects of the compounds 
AVM 001, AVM 002, AVM 010, AVM 011, AVM 014, AVM 015, AVM 019.  
Method is based on the cleavage of a yellow tetrazolium salt 3-{4,5-dimethylthiazol-2-
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yl}-2,5 diphenyl tetrazolium bromide (MTT) to purple formazan crystals by 
mitochondrial enzymes of metabolically active cells. 
 Cells were seeded with filter-sterilized compounds described in cell viability for 
24 hours, 48 hours, and 72 hours at 37°C with 5% CO2 humidified incubator. Three 
hours before the end of each incubation period, MTT stock solution (5 mg/ml) was 
added into each well at 1:10 ratio and incubated then plates were centrifuged at 1800 
rpm for 10 minutes at room temperatures in a plate rotor of Hettich 30 RF Centrifuge to 
avoid accidental removal of formazan crystals. Supernatant removing by tapping on a 
paper towel was followed DMSO (150 µl) addition and mixing on an orbital shaker at 
150 rpm for 5 minutes. The absorbance values were determined at 540 nm (690 nm 
reference wavelength) by using an automated plate reader (Organon Teknica Reader 
230S, Version 1,22). 
 
 
 
 
 
 
 
 
  
Chapter 4 
 
RESULTS AND DISCUSSION 
 
4.1. Solubility Properties of the Compounds 
Nineteen newly synthesized compounds (structures of compounds were given in 
Materials and Methods section) were examined in Lysis Buffer (LB) of reverse 
transcriptase RT assay, DMSO, ethanol or in methanol and also their 100 % solubilized 
form were diluted in Lysis buffer (LB) and RPMI 1640 to detect precipitate formation.  
First 1 mg compound was solubilized in 500 µl of LB. Except AVM 017; none 
of the compounds were solubilized in LB. Because of the high inhibitory effect of the 
Ethanol on RT, it was not preferred as a first choice for solubilization of compounds. 
Therefore, it was only chosen for compounds, which was not dissolved in DMSO. In all 
experiments AVM 001 and AVM 002 were dissolved in ethanol. Remaining 
compounds were solubilized in DMSO. AVM 008 and AVM 016 became solubilized 
after long time vortexing. All dissolved compounds in 100 % solvent formed 
precipitation when over 500 µM concentration were used to dilute in RPMI. Solvent 
concentration was fixed at 2 % for all RT inhibition experiments, 1 % for all cell 
culture. Solubilization properties of compounds in 100% solvent were given in Table 
4.1. 
 
Compound Lysis buffer 
Methanol 
100% 
Ethanol 
100% 
DMSO 
100% Compound 
Lysis 
buffer 
DMSO 
100% 
AVM 001 - + + - AVM 011 - - 
AVM 002 - + + - AVM 012 - - 
AVM 003 - + + + AVM 013 - - 
AVM 004 -   + AVM 014 - - 
AVM 005 -   + AVM 015 - - 
AVM 006 -   + AVM 016 - - 
AVM 007 -   + AVM 017 + + 
AVM 008 -   + AVM 018 - - 
AVM 009 -   + AVM 019 - - 
AVM 010 -   +  
 
Table 4.1. Solubilization properties of compounds in different solvents. 
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4.2. Inhibitory Effects of Compounds on Reverse Transcriptase Enzyme Activity 
Before the examination of compounds on RT, RT inhibition effects of ethanol 
and DMSO were determined. Figure 4.1.A shows that DMSO in range of 0-10 % did 
not have any effect on the activity of RT enzyme. However, the inhibitory effect of 
ethanol on RT enzyme given in Figure 5.1.b started at 2 % concentration and inhibitory 
effect gradually increased until 16% of ethanol and stayed at the same level in the 
presence of 33 % ethanol concentration (Figure 4.1.B). It was found that ethanol had 
higher inhibition effect than DMSO. Thus, DMSO was preferred as a first choice to 
solubilize the compounds (Barnard et al., 1997, Xie et al., 1999, Hashimoto et al.,1997). 
RT inhibitory effect of DMSO 
RT inhibitory effect of ethanol 
 
Figure 4.1. RT inhibition effect of DMSO (A) and ethanol (B). The experiment was 
carried as duplicate. The difference between OD values of each duplicate sample 
was less than 5%. 
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Compounds, dominantly designed as benzaxozale derivatives especially AVM 
002 [5-methyl-2-(fenoksymethil)benzaxozole] and AVM 014 [2-(p-florophenil)-5-
aminobenzaxozole] at 100 µM concentration showed 51.5 % and 43 % inhibitory effect 
respectively, Figure 4.2.A shows inhibition effect of AVM 002 on RT enzyme. AVM 
002 concentration at 0.01µM resulted in 29 % enzyme inhibition and inhibition at 1 µM 
was very close to 50 % inhibition. In the dose-response graph a decline to 22.5% in the 
inhibition was observed at 10 µM concentration. However, % RT inhibition was 
reached to 51.5% at 100 µM concentration point of AVM 002. As it can be seen in 
Figure 4.2.B, AVM 014 also showed good inhibition effect on RT enzyme. Percent 
inhibition of RT enzyme activity increased to 26.9% at 1µM concentration. However, 
percent inhibition decreased at 10µM to 19% inhibition and, and reach 43 % inhibition 
at 100µM concentration. 
 
 
 
 
 
 
 
 
 
Precent  inhibitory effect of AVM 002 on RT 
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Figure 4.2. Inhibitory effect of AVM 002 (A) and AVM 014 (B) on RT. Data are 
the average of separate three experiments for AVM 002 and separate two 
experiments for AVM 014. (Standard error of each point is given in table 4.2). 
Figure 4.3. represents dose-response curves of AVM 015, AVM 010, AVM 001, 
AVM 011 and AVM019. When concentration of AVM 015 was increased, inhibition 
rate increased and reached 30% and 36% inhibition at 10µM and 100µM of AVM 015, 
respectively (Figure 4.3.A). Figure 4.3.B shows inhibition effect of AVM 010 on RT 
enzyme. Inhibition effect of the compound was found around 5 % at 0.01 µM, 1 µM 
and 10 µM concentrations but inhibition effect of AVM 010 on RT enzyme picked to 
34.3 % inhibition at 100 µM compound concentration. Dose-response curve of AVM 
001 was given in Figure 4.3.C. At 0.01µM compound concentration; percent inhibition 
was at 28 %. It was sharply increased with 1µM and 10µM concentrations and reached 
to 32% and 42% inhibition. At 100 µM, there was decrease in inhibition effect on RT 
enzyme to 38 % was obtained. Inhibition effect of AVM 011 showed gradually increase 
at compound concentration from 0.01 µM and continued through to 1 µM, 10 µM and 
reach to 7.4%, 17.9 % and 25.8 % respectively. This increase stopped at 10 µM 
concentration reached 25.3 % RT inhibition effect (Figure 4.3.D.) at 100µM. According 
to results obtained from experiments with AVM 019, the inhibitory effect on the 
enzyme picked to 23.8 % at 1 µM compound concentration. The inhibitory effect of the 
compound at 10 µM decreased to 17% and followed by an increase at 100 µM 
compound concentration to 27.6 % RT inhibition (Figure 4.3.E). 
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Percent inhibitory effect of AVM 010 
Percent inhibitory effect of AVM 001 
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Percent  inhibitory effect of AVM 019 
Figure 4.3. Percent inhibitory effects of AVM 001 (A), AVM 010 (B), AVM 011 
(C), AVM 015 (D) and AVM 019 (E) on RT activity. Data are the average of 
separate three experiments for AVM 001 and AVM 011, separate two experiments 
for AVM 010, AVM 015 and AVM 019. (Standard error of each point is given in 
table 4.2). 
 
Meaningfull RT inhibition effects were not observed for another compounds. 
Therefore, they were not used rest of the experiments in this study.  
Table 4.2 shows summary of the effects of the compounds on RT activity and 
percent variation between separate experiments. High variation between separate 
experiments depends on varying assay conditions for example unstable laboratory 
temperature, as it reported in the literature (De Clercq, 1998). Determination of the EC50 
(50% effective concentration, or required to inhibit HIV-1 induced cytopathicity) values 
can show utility of the compounds for HIV-1 (+) patient. 
 
 
 
 
 
 
 
 
Table 4.2. Summary of the % inhibition effects of the compounds on RT activity 
and percent variation between separate experiments (Results are percent 
inhibitory effect). 
 Concentration 
Compounds 0 0.01 1 10 100 
AVM 001 0 28.2±4 32.2±8 42±8 38.4±6 
AVM 002 0 29±5 46±7 22.5±10 51.5±3 
AVM 010 0 7±1 6±1 0±0 34.3±6 
AVM 011 0 7.4±0 17.9±2 25.8±5 25.3±8 
AVM 014 0 3.6±2 26.9±2 19±6 43±5 
AVM 015 0 21±3 16±5 30±2 36±3 
AVM 019 0 0±0 23.8±5 17±6 27.6±4 
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FDA approved NNRTIs Nevirapine, Dalavirdine, and Efavirenz 
(Benzoxazinone) have 0.084 µM 0.26, µM and 0.003 µM IC50 (50 % inhibitory 
concentration, or concentration required to inhibit HIV-1 RT activity by 50 %) 
respectively (De Clercq, 1996, Merluzzi et al., 1990, Koup, et al., 1991, Dueweke, et 
al., 1993, Young, et al., 1995). It is important to note that for all of these compounds 
whether approved or compounds in clinical trials generally show highly reduced EC50 
(50 % effective concentration, or concentration required to inhibit HIV-1 induced 
cytopathicity by 50 %) value when compared with IC50. This manner means that 
activity of newly synthesized compounds can be observed at reduced concentration 
when assayed with infected cell lines. In addition, compounds that did not show 
inhibitory activity on HIV-1 RT can be active for resistant strains.  
Chemical structure of benzaxazole is given in Figure 4.4. As it can be seen 
AVM 002 seems to fit better for hydrophobic pocket of HIV-1 RT than the others when 
they were compared with the other compounds showed inhibitory effect on RT, 
especially AVM 010. CH3 group at Y position gave the best result. In addition, AVM 
0014 also showed IC50 value at 100µM concentrations and for this compound N2H 
molecule at Y position and F atom at Q position resulted with high inhibition effect on 
RT enzyme. 
Oxygen at X position found in benzaxozoles seems to be necessary to get high 
HIV-1 RT inhibition effect when the inhibitory activities of benzaxazoles is compared 
with benzymidazoles, because AVM 010 that belongs to benzaxozole group and AVM 
013 from benzimidazole group have the same structure except substitution of X.  AVM 
010 has oxygen atom in this position instead of NH and showed high inhibition. AVM 
007 also is benzimidasole and has close structure with AVM 010 but Q group is an 
hydrogen atom. We suggest that Cl group in Q position is not important for RT 
inhibition. AVM 015 and AVM 019 have different structure than other tested 
compounds (Figure 4.5).  
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 Y A X Z Q R 
AVM 001 Cl H O - CH3 O 
AVM 002 CH3 H O -CH2-O- H O 
AVM 010 H H O -CH2-O- Cl O 
AVM 011 H O2N O - H - 
AVM 014 H2N H O - F O 
 
Figure 4.4. Substitutions in benzaxazole derivatives. 
 
 
Figure 4.5. Structures of AVM 015 and AVM 019.           
       
Since there are no structurally related compounds with newly synthesized 
benzaxazoles and benzimidazoles and determined RT inhibitory activities in literature, 
comprehensions were done by using data obtained from this study and literature of FAD 
approved compounds. 
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4.3. Effect of Compounds on Cell Viability of PBMC 
Compounds that showed RT inhibition between 20-50 percent were examined to 
determine the effects on viability of PBMC. Concentration points at 1000 µM, 500 µM, 
100 µM, 1 µM, 0.1 µM and 0.01 µM per well were used to plot the dose response curve. 
Dilutions were set and calculated to obtain 1% solvent concentration per well. All 
dilutions were prepared just before the experiments. Stored dilutions were not used to 
avoid any change in compound structure. 2 x 105 cells per well were used. And cells 
were incubated in the culture medium containing compound at different concentrations 
for one, two or three days in order to see if compound has any toxic effect on cell 
viability. Culture medium with the cells without compound served as control in all 
viability experiments.  
AVM 001 caused little decrease in cell viability at the end of first 24 hours at all 
concentrations examined. There was only 12% decrease in cell viability of cells 
incubated with 0.01µM concentrations of AVM 001. For 48 and 72 hours, 25 % and 29 
% decline were observed in the wells having 1000 µM compound concentration (Figure  
4.6).  
Figure 4.6. Effects of AVM 001 on the cell viability of PBMC. Data are the average 
of two different experiments. 
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observed with 500µM compound at the end of day 1,2, and 3, respectively. Similarly, 
1000µM compound resulted in 48%, 54%, and 54% decrease in cell viability at the end 
of day 1,2, and 3. These results imply that compound AVM 002 has toxic effect on the 
cell viability at 500µM and 1000µM concentrations, compared to control. 
 
Figure 4.7. Effects of AVM 002 on cell viability of PBMC. Data are the average of 
two different experiments. 
 
As with similar to compound AVM 002, the compound AVM 014 did not show 
toxic effects on the cell viability at concentrations from 0.01 to 100µM, compared with 
controls (Figure 4.8). When the results obtained from day 1 at all concentrations are 
compared to each other, viability stayed almost at the same level, around 90%. Similar 
pattern of effect on cell viability was observed at the end of day 2 and 3 until compound 
concentration increased to 100µM. However, cell viability decline to about 40% at the 
end of day 2 and 3 in the presence of compound at 500µM and 1000µM concentration. 
Taken together, AVM 014 had toxic effect at 500µM and 1000µM concentrations.  
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Figure 4.8. Effects of AVM 014 on the viability of PBMC. Data are the average of 
two different experiments. 
 
Even though AVM 010 showed similar pattern with other compounds until 
100µm concentration, it was the most toxic one when compared with the others at 
500µM and 1000µM concentration where cell viability was observed to be less than 
40% at the end of day 1, 2, and 3 (Figure 4.9). 
 
Figure 4.9. Effects of AVM 010 on the cell viability of PBMC. Data are the average 
of two different experiments. 
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The cell viability was around 80% and more at all concentrations of AVM 011 
compound at the end of day 1, 2, and 3 (Figure 4.10). The decrease in the viability was 
around 19% even at 1000µM concentration, compared to the control. Therefore, AVM 
011 was less or not toxic at 500µM and 1000µM concentrations when it was compared 
with previous compounds. 
 
Figure 4.10. Effect of AVM 011 on cell viability of PBMC. Data are the average of 
two different experiments. 
 
The compound AVM  015 did not show any effect on the viability of PBMC. 
For all three days,cell viability was found over 90 % (Figure 4.11), indicating that AVM 
015 is not toxic on cell viability. 
Figure 4.11. Effect of AVM 015 on cell viability of PBMC. Data are the average of 
two different experiments. 
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The viability of PBMC treated with AVM 019 did not change after treatment 
with the compound until 1000µM concentration at the end of day 1, 2 (Figure 4.12). 
However, there was 28% and 48% decrease in the cell viability after day 2 and 3 at 
1000µM compound concentration.  
 
Figure 4.12. Effect of AVM 019 on cell viability of PBMC. Data are the average of 
two different experiments. 
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concentration, or concentration required to reduce viability of the host cells by 50 %) 
respectively (De Clercq, 1996, Merluzzi et al., 1990, Koup, et al., 1991, Dueweke, et 
al., 1993, Young, et al., 1995). CC50 values of the tested compounds were higher than 
or equal to 500µM concentration. When the CC50 values of the FDA approved 
compounds are compared with the CC50 values of AVM 001 (>1000µM), AVM 002 
(CC50=500µM), AVM 010 (between 100µM-500µM), AVM 011(>1000µM), AVM 014 
(CC50=1000µM), AVM 015 (>1000µM) and AVM 019 (>1000µM), it can be easily 
seen that newly synthesized compounds have good cytotoxic profiles than Nevirapine, 
Dalavirdine, and Efavirenz. Table 4.3 shows the summary of the effects of the 
compounds on cell viability. 
 
  Concentrations (µM) 
Compounds Days 0 0.01 0.1 1 100 500 1000 
1 96±2 90±0 90±0 87±4 86±1 74±5 74±4 
2 95±1 88±1 87±1 86±4 78±5 77±5 70±5 AVM 001 
3 83±1 76±1 66±1 73±4 59±5 66±5 54±5 
1 97±2 97±1 98±0 96±2 97±1 62±2 49±2 
2 90±3 97±1 97±1 97±1 98±2 46±1 38±4 AVM 002 
3 93±1 97±0 97±0 96±4 94±2 54±1 38±5 
1 94±4 92±1 84±5 91±1 80±4 38±4 31±5 
2 91±1 93±2 90±0 91±1 77±2 34±2 24±3 AVM 010 
3 91±3 89±0 87±1 88±3 77±3 38±3 22±3 
1 94±3 95±1 93±2 90±2 92±1 82±5 75±1 
2 97±1 93±1 95±1 94±0 92±2 93±5 83±4 AVM 011 
3 92±1 88±3 92± 77±5 85±2 76±4 75±1 
1 94±2 94±1 94±1 91±2 95±1 92±1 80±3 
2 92±1 90±4 90±3 85±2 86±4 48±5 53±5 AVM 014 
3 82±5 82±1 83±5 81±2 84±5 70±2 48±0 
1 99±1 100±0 99±1 100±0 100±0 99±0 98±2 
2 99±1 98±2 98±0 98±1 99±1 98±1 97±3 AVM 015 
3 98±0 99±5 95±1 97±1 96±3 96±4 94±5 
1 98±2 99±1 98±1 97±1 98±0 91±1 87±5 
2 99±1 97±5 99±1 99±2 93±2 91±5 83±1 AVM 019 
3 95±2 94±0 93±2 90±3 90±1 74±1 56±3 
 
Table 4.3. Summary of the effects of the compounds on cell viability. Data are the 
average of two different experiments. Variation between two experiments was 
because of biological differences between two blood donors. 
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4.4. The Effects of Compounds on Proliferation of PBMC 
Effects of compounds on the proliferation of PBMC were determined by using 
cell proliferation ELISA kit. Concavalin A (Con A) and phytohemoglutine (PHA) were 
used as a mitogen in the assay. 200 µg/ml of Con A and PHA that previously 
determined were used to obtain maximum proliferation of PBMC.  
Effect of the compounds that showed inhibitory effect on RT, except AVM 015 
and AVM 019 on the cell proliferation were determined by the cultivation of PBMC in 
the absence and presence of Con A or PHA. Increased optical density indicates that 
compound stimulates PBMC to proliferate. 
AVM 001 caused 2.2 fold increase in cell proliferation when compared with the 
control at concentration of 1 µM. AVM 002 caused 2.5 fold increase at the same 
concentration. IC50 of AVM 002 was found at 100 µM and this concentration did not 
cause any change in cell proliferation when compared with control. However, 1000 µM 
concentration it had toxic effect on the cell viability. Same toxic effect was obtained at 
the same concentration for AVM 001 (Figure 4.13.A and B). 
When PBMC were cultured with AVM 014, linear decline in the cell 
proliferation was obtained through the 1000 µM compound concentration (Figure 
4.13.C).  There was 82% decrease at 1000µM concentration compared to the control 
without AVM 014.  
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Figure 4.13. Effects of AVM 001 (A), AVM 002 (B) and AVM 014 (C) on 
proliferation of PBMC.  Data are the average of duplicate samples. 
 
AVM 010 (Figure 4.14.A) and AVM 011 (Figure 4.14.B) caused a decrease in 
cell proliferation when compared with control at all concentrations examined. At 100 
µM concentration 2 fold decrease for AVM 010, 6 fold decrease for AVM 011 in cell 
proliferation were obtained. 100µM was the most toxic concentration of AVM 011 on 
cell proliferation when compared with the controls. In other words, AVM 010 and 
AVM 011 both had toxic effect on the cell proliferation.  AVM 015 (Figure 4.14.C) 
gave totally different cell proliferation effect. Small concentrations of the compound 
caused decline in proliferation of PBMC but cell proliferation rate gradually increased 
at 500µM and 1000µM concentration. AVM 019 (Figure 4.14.D) appears to stimulate 
cell proliferation of PBMC compared to control (Table 4.4). 
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Figure 4.14. AVM 010 (A), AVM 011 (B), AVM 015 (C) and AVM 019 (D) on 
proliferation of PBMC. Data are the average of duplicate samples. 
 
 Concentrations 
Compounds 0 0.1 1 100 500 1000 Con A/PHA 
AVM 001 22.5 39.5 50 31 46.5 0 250 
AVM 002 26.5 5 68 28 25 0 150 
AVM 010 349 208 265 168.5 210 184 222 
AVM 011 262 106 144 43.5 126 140 222 
AVM 014 126 85 68 81 69 32 260 
AVM 015 216 49 33 47 113 155 260 
AVM 019 28 83 38 64 48 15 260 
 
Table 4.4.  Summary of the effects of the compounds on cell proliferation and 
percent variation between separate experiments. Results are average of OD values 
of duplicate samples. Differences between absorbance values of duplicate samples 
were less than 5% in all experiments. 
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HIV causes AIDS disease when immune system of a body is so damaged and 
immunological abnormalities start to occur. This manner means having less than 200 
CD4+ cells. Additional decrease in cell proliferation due to use of drugs can cause 
increase in the probability of death because of the opportunistic infections especially at 
the last period of HIV infection. Therefore, AVM 010 and AVM 011 are not useful as 
an anti-HIV chemotherapeutics because they caused a decrease in cell proliferation. 
Change in the structure of AVM 014 should be focused to decrease the adverse effects 
on the biological parameters. Since AVM 019 caused an increase in cell proliferation, it 
seems to be safe according to this parameter. Other compounds require additional tests 
with infected cell lines. Because AVM 015 caused increase in cell proliferation at high 
concentration and has over 1000µM CC50 value, it can be useful in mega-HAART 
(Highly Active Antiretroviral Therapy) program. The aim of this therapy is to normalize 
the white blood cell count, decrease production of viral particles and make the immune 
system start to work by inhibiting the enzymatic pathways of HIV-1.  
Other compounds examined on cell proliferation are AVM 003, AVM 004, 
AVM 005, AVM 006, AVM 007, AVM 009, AVM 012, AVM 013 and AVM 017. 
AVM 003 caused an increase (1.3 fold) at 1 µM concentration and 0.6 fold decrease at 
100 µM concentration followed by small increase at 1000µM that was close to control. 
AVM 004 showed an increase in cell proliferation for all concentrations. In other words, 
AVM 004 had stimulatory effect on cell proliferation and can be developed as an 
immunostimulant. AVM 006 and AVM 007 did not show any significant change in cell 
proliferation. Proliferation rate fluctuated between 200 and 150 OD values at all 
concentrations of AVM 006. Remaining compounds AVM 005, AVM 009, AVM 012, 
AVM 013, and AVM 017 caused significant decline in proliferation of PBMC 
compared to the control indicating that these compounds have inhibitory effect on cell 
proliferation (Table 4.5). In Table, values over 1 indicate that tested compound 
stimulates PBMC to proliferate. Relative level of the cell proliferation was calculated by 
the following equation: 
 
Relative Level of Cell Proliferation= Optical Density of the Sample / Optical Density of 
the Control 
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 Concentration 
Compounds 0 0.1 1 100 500 1000 
AVM 003 1 0.4 1.32 0.64 0.73 0.97 
AVM 004 1 1.15 1.42 1.23 1.15 1.48 
AVM 005 1 0.44 0.54 0.46 0.41 0.362 
AVM 006 1 0.76 0.97 0.73 0.67 0.78 
AVM 007 1 0.9 0.83 1 0.86 0.95 
AVM 009 1 0.42 0.69 0.44 0.36 0.61 
AVM 012 1 0.1 0.23 0.16 0.28 0.26 
AVM 013 1 0.13 0 0.25 0.45 0.27 
AVM 017 1 0.14 0.62 0.3 0.33 0.44 
 
Table 4.5. Summary of the effects of compounds AVM 003, AVM 004, AVM 005, 
AVM 006, AVM 007, AVM 009, AVM 012, AVM 013 and AVM 017 on cell 
proliferation (Results are the ratio of OD values of the compound to OD values of 
the control without compound). Data are the average of duplicate samples. The 
difference between OD values of duplicate samples was less than 3%. 
 
5.5. AMES Mutagenicity Test 
Mutagenic effects of compounds AVM 001, AVM 002, AVM 010, AVM 011, 
AVM 014, AVM 015 and AVM 019 were determined by AMES test. Compounds were 
dissolved in DMSO and each compound was examined at 0.01µM, 0.1µM, 1µM, 
100µM, 1000µM and 3000µM concentration points. 100µl compound solute was mixed 
with 100µl bacterial culture. In this test, Salmonella typhimurium TA 100 and TA 102 
strains were used. After 48 hours incubation at 37oC, the number of revertant colonies 
with background lawn were counted and compared with the positive control (sodium 
azide and sunlight) and the negative control without any compounds. Because Sodium 
azide and sun light are known as mutagenic agents, they were served as a positive 
control in this current study. Since mutations is the main cause of the cancer 
chemotherapeutics do not have any mutagenic effects on the body. As a result, none of 
the newly synthesized compounds showed mutagenic effect on Salmonella TA 100 and 
TA 102. However, AVM 001 and AVM 002 showed anti-bacterial effect on Salmonella 
tester strains TA 100 and TA 102 (Figure 4.15, 4.16, Table 4.6 and 4.7); therefore, no 
colony was observed in the plate. 
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Table 4.6. Mutagenic effects of the compounds AVM 001 AVM 001, AVM 002, 
AVM 010, AVM 011, AVM 014, AVM 015 and AVM 019 on TA 100 Salmonella 
strain and percent variation between duplicate samples. 
 
 
Table 4.7. Mutagenic effects of the compounds AVM 001 AVM 001, AVM 002, 
AVM 010, AVM 011, AVM 014, AVM 015 and AVM 019 on TA 102 Salmonella 
strain and percent variation between du plicate samples.
 Compound Concentrations Mutagen 
Compounds 0 0.01 0.1 1 100 1000 3000 Sodium Azide 
AVM 001 93±2 0 0 0 0 0 0 1736±5 
AVM 002 99±6 0 75±25 8±0 0 0 0 1168±19 
AVM 010 82±7 66±6 60±5 62±13 65±5 69±14 76±4 1512±5 
AVM 011 85±16 68±5 65±3 69±0 69±2 90±7 151±6 1540±4 
AVM 014 85±10 55±7 61±12 58±5 62±1 60±3 74±4 740±0 
AVM 015 77±28 57±4 49±0 63±20 54±40 59±3 68±10 878±50 
AVM 019 63±4 63±12 63±40 67±21 67±0 72±21 80±23 882±11 
 Compound Concentrations Mutagen 
Compounds 0 0.01 0.1 1 100 1000 3000 Sun Light 
AVM 001 175±5 0 21±10 9±5 0 191±20 2±2 500±10 
AVM 002 213±30 163±3 55±38 98±3 4±22 0 0 350±18 
AVM 010 152±10 150±5 162±23 134±21 156±2 143±8 134±3 648±5 
AVM 011 363±10 98±4 192±2 244±8 132±20 184±6 323±23 500±4 
AVM 014 153±12 148±24 103±11 143±15 169±2 170±0 163±1 318±0 
AVM 015 190±25 88±5 104±4 119±13 71±10 116±0 92±3 300±10 
AVM 019 150±0 61±6 96±4 91±6 102±30 108±6 91±3 310±0 
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Figure 4.15. Mutagenic effects of the compounds AVM 001, AVM 001, AVM 002, AVM 010, AVM 011, AVM 014, AVM 015 and 
AVM 019 on TA 100 Salmonella strain (Results are the average of duplicate samples) 
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Figure 4.16. Mutagenic effects of the compounds AVM 001, AVM 001, AVM 002, AVM 010, AVM 011, AVM 014, AVM 015 and 
AVM 019 on TA 102 Salmonella strain (Results are the average of duplicate samples)
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4.6.Activation Effects of The Compounds on PBMC 
 The activation effects of the compounds were examined by using MTT assay. Six 
different concentrations of the compounds (0.01µM, 0.1µM, 1µM, 100µM, 500µM, and 
1000µM) were prepared and filter sterilized. In order to keep DMSO or ethanol concentration 
at the constant level per well, 100% pure solvent dilutions were prepared. After that, fixed 
amount of dissolved compounds were pipetted in to RPMI. Cells were treated with 
compounds at optimum cell culture conditions for 24, 48 and 72 hours. MTT was added 3 
hours before the end of each incubation period. Formazan crystals formed by active cells were 
dissolved and absorbance of formed purple solutions directly represents the cellular activity. 
AVM 001 and AVM 011 did not show significant effects on the activation of PBMC when 
each day was compared with the controls (Figure 4.17.A and B). 
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Activation Effect of AVM 011 on PBMC  
Figure 4.17. Activation effects of AVM 001 (A) and AVM 011 (B) on PBMC. Data are 
the average of the separate experiments. 
AVM 002, AVM 014, AVM 010 and AVM 019 caused decrease in cell activation 
especially at 500 µM and 1000 µM. AVM 014 and AVM 019 showed effect at the end of the 
48 and 72 hours (Figure 4.18). 
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Activation Effect of AVM 014 on PBMC 
 
Activation Effect of AVM 019 on PBMC 
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Activation Effect of AVM 010 on PBMC 
Figure 4.18. Activation Effect of AVM 002 (A), AVM 010 (D), AVM 014 (B) and AVM 
019 (C) on PBMC. Data are the average of the separate experiments. 
 
AVM 015 caused increase in cell activation of PBMC at 500 µM and 1000 µM 
concentration. The curve was similar with proliferation effect of the compound (Figure 4.19, 
Table 4.8). 
Figure 4.19. Activation Effect of AVM 015 on PBMC. Data are the average of the 
separate experiments. 
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  Concentrations 
Compounds Day 0 0.01 0.1 1 100 500 1000 
1 341±2 310±2 293±2 295±2 352±4 403±0 338±0 
2 275±1 261±10 236±1 230±2 228±0 287±3 303±4 AVM 001 
3 241±1 288±10 302±1 246±2 219±0 225±3 230±3 
1 210±2 239±0 249±0 246±0 226±1 98±5 97±5 
2 203±3 210±3 215±0 193±5 173±3 71±3 76±6 AVM 002 
3 220±4 202±5 200±0 229±2 169±10 73±1 82±2 
1 227±2 239±0 238±2 226±0 198±0 97±2 118±0 
2 222±2 200±3 170±4 201±8 144±2 82±5 85±0 AVM 010 
3 216±5 170±7 139±10 199±10 108±2 86±1 100±2 
1 218±3 222±7 212±6 210±7 195±7 199±6 200±10 
2 202±3 304±3 168±3 164±10 157±2 169±4 166±6 AVM 011 
3 233±1 177±2 170±5 168±1 155±1 163±2 150±1 
1 211±4 220±3 200±10 202±5 220±0 158±6 147±3 
2 221±1 192±7 196±5 196±7 174±9 71±2 68±1 AVM 014 
3 239±4 171±10 170±5 177±4 145±2 69±1 69±2 
1 311±5 246±1 238±7 271±10 250±10 466±3 560±5 
2 305±4 210±5 217±10 219±3 244±10 377±0 419±2 AVM 015 
3 246±3 117±5 203±9 210±8 219±4 317±2 353±3 
1 294±4 271±10 275±10 297±5 269±5 164±7 258±04 
2 225±4 242±1 206±1 239±2 208±2 67±3 100±0 AVM 019 
3 231±0 204±4 218±3 114±5 180±1 47±6 150±8 
 
Table 4.8. Summary of the effects of the compounds AVM 001, AVM 002, AVM 010, 
AVM 011, AVM 014, AVM 015 and AVM 019 on cell activation. Results are average of 
OD values from separate experiments. 
 
It can be concluded that AVM 001 and AVM 011 do not have any significant effect on 
the activation of the PBMC. AVM 002 and AVM 010 caused decline on the cell activity at 
500µM and 1000µM concentrations at the end of three days. This decline can be caused from 
the accumulation of the compounds in cells. AVM 014 and AVM 019 caused decline in cell 
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activation especially at the end of second and third day and it can be caused from the 
metabolite accumulation. This is because; animal tests should be applied to find the reasons of 
this decline.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Chapter 5 
 
CONCLUSIONS AND FUTURE EXPERIMENTS 
 
5.1.Conclusion 
In summary, HIV-1 RT inhibitory effects of the 19 compounds at the 
concentrations from 0.01 to 100 µM were investigated. For this aim, newly synthesized 
compounds were tested by using non-radioactive ELISA kit from Roche. Compounds 
AVM 001, AVM 002, AVM 010, AVM 011, AVM 014, AVM 015 and AVM 019 that 
showed RT inhibition in range of 0-100 µM were evaluated. In order to show blood cell 
effects, 3 parameters were investigated. These were viability, proliferation and 
activation of the Peripheral Blood Mononuclear Cells (PBMC). Effect of compounds on 
the viability of PBMC by trypan blue dye exclusion method, on the proliferation of 
PBMC by incorporation of bromodeoxyurudine to DNA in the proliferating cells and on 
the activation of PBMC by MTT test were examined. Determination of the mutagenic 
potentials of the compounds was performed by AMES test (Salmonella typhimurium 
reverse mutation test). 
5-methyl-2-(phenoxymethyl) benzoxazole named as AVM 002 and AVM 014 
(2-(p-fluorophenyl)-5-aminobenzoxazole) were found as the most promising 
compounds according to their RT inhibition effect when compared with inhibitory 
activity on RT of remaining compounds. IC50 (50 % inhibitory concentration, or 
concentration required to inhibit HIV-1 RT activity by 50 %) value of AVM 002 was 
found at 100µM concentrations. At the same concentration AVM 014 also showed 43% 
RT inhibition activity. Fifty percent cytotoxic concentration on PBMC (CC50; 50% 
cytotoxic concentration, or concentration required to reduce viability of the host cells by 
50 %) was observed at 500 µM. For other compounds, IC50 value was not found in the 
range of 0.01 µM-100 µM. At 100 µM concentration, compounds AVM 001, AVM 015, 
AVM 010, AVM 019, AVM 011 showed 38.4 %, 36 %, 34 %, 27 %, 25 % inhibitory 
effects on RT activity, respectively. Therefore, AVM 002 and AVM 014 can be 
evaluated by small modifications in compound structure to get higher RT inhibitory 
activity. 
PBMC treated with AVM 001 at 1000µM concentration indicated 80 % viability 
at the end of 24 and 48 hours. Fourtyfive percent decline in the cell viability was 
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observed at the end of 72 hours only for the highest concentration and CC50 value was 
over 1000µM. AVM 002 and AVM 010 caused 50 % decrease in the viability of PBMC 
for 500 µM and 1000 µM compound concentration at the end of 24, 48 and 72 hours. 
CC50 of AVM 002 was equal to 500µM. AVM 010 was the most toxic one when 
compared with the dose-response curve of the other compounds, because at 1000 µM 
concentration 63 %, 67 % and 69 % decline in the cell viability were determined at the 
end of 24, 48 and 72 hours, respectively.  CC50 of AVM 010 was found between 
100µM-500µM concentrations. At the same concentration, AVM 014 also caused 
nearly 50 % decrease after 48 hours and 72 hours incubation. AVM 011, AVM 015 did 
not show any toxic effect on the viability of the PBMC at all the concentrations tested. 
In other words, CC50 values of AVM 011 and AVM 015 was over 1000µM 
concentrations for the cell viability. AVM 019 was toxic only at the end of third day at 
1000µM concentration. As a result, the toxic effect of the compounds may be due to the 
compound structure, accumulation of compound in cells especially in the presence of 
high dose compound, or accumulation of the metabolite especially at the end of 48 and 
72 hours. In vivo modeling of compound metabolism can explain the reasons of the 
toxicity and determine the dosage that should be used for HIV–1(+) individual.  
Effects of the compounds on the proliferation of the PBMC varied. When 
compared with the control, AVM 001 caused 2.2-fold increase at 1 µM concentration 
and AVM 002 also caused 2.5-fold increase at the same concentration. In addition, IC50 
value of AVM 002 (100µM) did not lead to any change on the proliferation of PBMC 
but decline in this parameter at 1000 µM concentration was observed for both AVM 001 
and AVM 002. AVM 014 resulted in a linear decline until the highest concentration, 
1000 µM at which 3 fold decline was obtained. AVM 010 and AVM 011 also caused 50 
% decrease on this parameter when compared with the control. While AVM 019 was 
found to stimulate the cells to proliferate, AVM 015 caused quite different proliferation 
profile. AVM 015 at 0.01µM concentration gave rise to 75% decrease in cell 
proliferation, compared to the control; when the concentration increased, cell 
proliferation rate rose.  Inhibition of cell proliferation can lead to immune suppression 
and make the body more susceptible to infections. Since AIDS patients have less than 
200 CD4+ cells, additional decrease in cell proliferation depending on the usage of 
drugs can cause increase in the probability of death due to the opportunistic infections 
especially at the last period of HIV infection. Therefore, AVM 010 and AVM 011 are 
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not useful as an anti-HIV chemotherapeutics. Since AVM 019 caused increase in cell 
proliferation, it seems to be safe according to this parameter. Other compounds require 
additional tests with infected cell lines with HIV-1. In addition, AVM 004 can be 
evaluated as an immunostimulant.  
In addition, activation of PBMC in the presence of the compounds was evaluated 
and closely associated results were obtained with proliferation experiments. At the end 
of first 24 hours, AVM 001 caused a little increase at 100 µM and 500 µM 
concentrations but a decrease in the activation of PBMC was observed at the end of 72 
hours. PBMC treated with AVM 011 resulted in little decline at the end of 48 and 72 
hours when compared with the controls of each days. While 500 µM and 1000 µM 
concentrations of AVM 002 and AVM 014 caused around 60 % decline, other 
concentrations did not affect activation of PBMC. For the same parameter 500 µM 
AVM 019 caused 60 % decrease at the end of 48 and 72 hours but the cell activation at 
1000 µM concentration was higher than the activation of 500 µM AVM 019 treated 
wells. AVM 010 caused a gradual decrease depending on the increase in compound 
concentration. On the contrary, increased concentrations of AVM 015 caused elevation 
in cell activation and 500µM and 1000 µM concentrations resulted 25 % and 40 % 
increase, respectively. Therefore, it can be concluded that AVM 001 and AVM 011 do 
not have any significant effect on the activation of the PBMC. Decline on the cell 
activity at 500µM and 1000µM concentrations of AVM 002 and AVM 010 can be 
resulted from the accumulation of the compounds in cells. Decline in the cell activation 
especially at the end of second and third day of AVM 014 and AVM 019 exposure can 
be caused from the metabolite accumulation. This is because; animal tests should be 
applied to find the reasons of this decline.  
According to results of AMES reverse mutation test, none of the compounds 
have mutagenic effects on Salmonella typhimurium TA 100 and TA 102 strains when 
they were compared to the positive controls (sodium azide and sun light) and the 
negative control. 
As a result, especially AVM 002 and AVM 014 are the most promising 
compounds in regard to RT inhibition. A slight modification in their chemical structure 
of these compounds may give rise to significant increase in the inhibitory effects of 
them on RT enzyme. Such changes in their structure will allow us to investigate these 
compounds at the second stage level of drug development research. In other words, this 
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current study revealed the inhibitory effects of compounds on RT and completed the 
studies on the first stage of drug discovery. 
 
5.2. Future Experiments 
i. Structures of the compounds should be modified in order to increase RT 
inhibition effects and decrease cytotoxicity 
ii. Second generation compounds should be evaluated in vitro 
iii. Computer programs can be used to find fitness of compounds to 
hydrophobic pocket of HIV-1 RT enzyme in order to support in vitro 
results  
iv. Second generation compounds can be evaluated with HIV infected cell 
lines to find utility for HIV (+) individuals  
v. All compounds and also second generations should be assayed on 
resistant strains 
vi. In order to find half life of compounds, in vivo metabolism should be 
worked with animals  
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